Veregen® is an ointment used to treat external genital warts. In the USA and Canada, in 15 European countries (Germany, Austria, Switzerland, Spain, the Netherlands, Belgium, Norway, Denmark, Finnland, Sweden, the Czech Republic, Poland, Serbia, Hungary, Slovakia) and Taiwan Veregen® is already marketed by our partners. Sales and marketing partnerships are also in place for this drug in a large number of other countries in Europe, Asia and America. An overview of our partners can be found here. The sales generated with Veregen® are continually rising and making a valuable contribution to financing the Company.
As an innovative drug, Veregen® is based on a defined extract from green tea leaves obtained in a highly complex and specifically developed process
Medigene in-licensed the basic rights to the active ingredient of Veregen® in 1999 and then completed the clinical development of Veregen®. Subsequently, Medigene successfully obtained a marketing authorization by the approval process of the US Food and Drug Administration (FDA). Veregen® is the first, and to date one of a very small number of innovative plant-based drug approved by the FDA. Furthermore, Medigene is the first German biotech company to have a drug on the US market.
Veregen® is currently available in the US, in 15 European countries (Germany, Austria, Switzerland, Spain, Serbia, the Netherlands, Norway, Sweden, the Czech Republic, Slovakia, Hungary, Poland, Belgium, Denmark, Finland) as well as in Taiwan and Canada and was approved in further countries.
Medigene has marketing agreements for Veregen® with numerous partners worldwide in place. In April 2014, Medigene and the pharmaceutical company Kora Healthcare concluded an exclusive agreement for the supply and commercialisation of Veregen® in the United Kingdom and Ireland. Following marketing authorisation, Kora Healthcare will promote and distribute the drug.
Veregen® is also listed in recognized treatment guidelines. The US Center for Disease Control and Prevention In its current treatment guidelines for sexually transmitted diseases, recommends Sinecatechins 15% ointment (Veregen®) as a possible option for treating genital warts. In addition, the “2012 European Guideline for the Management of Anogenital Warts” includes Sinecatechins 10% & 15% ointment (Veregen®) as a recommended treatment option for genital warts.
Medigene anticipates the market launch of Veregen® in several other countries by the end of 2014. The Company is planning to file for approval in a further eight European countries under the mutual recognition procedure in the third quarter of 2014, including in the UK and Italy, two of the five biggest pharmaceutical markets in Europe.
Veregen® is a trademark of Medigene AG.
Polyphenon E® is a trademark of Mitsui Norin Co., Ltd.